EGFR and in situ carcinoma: Preclinical and clinical radioimmunotherapy, targeting epidermal growth factor receptor (EGFR), mainly expressed in CIS, with an antibody-radiolabeled with an alpha-emitting radionuclide (bismuth-213), has been proposed [13,14], but CIS accounts for only 10% of NMIBCs [10].